Court denies ImClone attempt to dismiss suit over Erbitux

07/31/2006 | MarketWatch

A U.S. court refused to dismiss a suit against ImClone Systems brought by Repligen Corp. and the Massachusetts Institute of Technology over patent rights for the cellular line used in creating Erbitux. ImClone sought dismissal on grounds the patents have expired. Repligen and MIT will seek compensation for the unlicensed use of the patented technology, the company said.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC